Abstract
With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 13-18 |
Number of pages | 6 |
Journal | British Journal of Cancer |
Volume | 100 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2009 |
Research programs
- EMC MM-03-49-01
- EMC MM-03-86-08